Latest Protease Stories
BRISBANE, Calif., Feb. 20 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) announced today that it will release fourth quarter and full-year 2008 financial results on Thursday, February 26, 2009 at 4:00 p.m. Eastern time.
BRISBANE, Calif., Jan. 9 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) today announced that it will conduct a conference call and webcast on Monday, January 12 at 8:30 a.m.
BRISBANE, Calif., Nov. 14 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that Daniel G. Welch, Chairman, Chief Executive Officer and President of InterMune, will present at Lazard Capital Markets 5th Annual Healthcare Conference on November 18, 2008 at 3:10 p.m. EST.
SOUTH SAN FRANCISCO, Calif., Oct. 28 /PRNewswire/ -- Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase(TM) therapeutics, has appointed Todd Lorenz, M.D., as the company's Chief Medical Officer. Dr.
After improving the sensitivity of nuclear magnetic resonance (NMR), researchers at the University of Missouri actually watched the HIV-1 protease mature from an inactive form into an active infection. This process has never been directly visualized before. The findings appear today in the journal Nature.
BRISBANE, Calif., Sept. 8 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that Steven B. Porter, M.D., Ph.D., Chief Medical Officer of InterMune, will present at the Robert W. Baird & Co. Small Cap Healthcare Conference in New York on September 10, 2008 at 10:30 a.m. EDT.
BRISBANE, Calif., Aug. 29 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that Daniel G. Welch, Chairman, CEO and President of InterMune, will present at the Thomas Weisel Partners Healthcare Conference in Boston on September 4, 2008 at 10:55 a.m. EDT.
BRISBANE, Calif., July 30 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that Daniel G. Welch, Chairman, CEO and President of InterMune, will present at the BMO Capital Markets 2008 Focus on Healthcare Conference in New York on August 6, 2008 at 10:00 a.m. EDT.
Roche has recalled HIV drug Viracept in Europe and other world regions, excluding the US and Canada, over a potential contamination. As one of the older protease inhibitors, Viracept is prescribed to few patients and its recall will not significantly change current HIV market dynamics.
A molecule consisting of two "cages" of metallic atoms bound to carbon has shown great promise in preliminary tests of becoming a new weapon in the anti-HIV arsenal, researchers at UT Southwestern Medical Center report. The molecule â€“ called metallacarborane â€“ and its variants appear to fight HIV protease, an enzyme critical in the virus' life cycle. Protease inhibitors are some of the key drugs used to fight HIV/AIDS, but they have side effects, and viruses can develop...